Power/sample size calculations for assessing correlates of risk in clinical efficacy trials

详细信息    查看全文

• 作者：Peter B. Gilbert ; Holly E. Janes and Yunda Huang
• 刊名：Statistics in Medicine
• 出版年：2016
• 出版时间：20 September 2016
• 年：2016
• 卷：35
• 期：21
• 页码：3745-3759
• 全文大小：1191K
• ISSN：1097-0258

文摘

In a randomized controlled clinical trial that assesses treatment efficacy, a common objective is to assess the association of a measured biomarker response endpoint with the primary study endpoint in the active treatment group, using a case-cohort, case-control, or two-phase sampling design. Methods for power and sample size calculations for such biomarker association analyses typically do not account for the level of treatment efficacy, precluding interpretation of the biomarker association results in terms of biomarker effect modification of treatment efficacy, with detriment that the power calculations may tacitly and inadvertently assume that the treatment harms some study participants. We develop power and sample size methods accounting for this issue, and the methods also account for inter-individual variability of the biomarker that is not biologically relevant (e.g., due to technical measurement error). We focus on a binary study endpoint and on a biomarker subject to measurement error that is normally distributed or categorical with two or three levels. We illustrate the methods with preventive HIV vaccine efficacy trials and include an R package implementing the methods. Copyright